• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • AstraZeneca's lung cancer therapy Tagrisso approved in China firstwordpharma
    March 28, 2017
    AstraZeneca announced Monday that the China Food and Drug Administration (CFDA) approved Tagrisso (osimertinib) for the treatment of adults with locally-advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service